109 related articles for article (PubMed ID: 19960790)
21. [The correlation of helper T lymphocyte 1/helper T lymphocyte 2 with clinical and image features in patients with idiopathic pulmonary fibrosis].
Peng SC; Hu X; Wei LQ; Li ZH
Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):489-93. PubMed ID: 24059996
[TBL] [Abstract][Full Text] [Related]
22. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Raghu G; Behr J; Brown KK; Egan JJ; Kawut SM; Flaherty KR; Martinez FJ; Nathan SD; Wells AU; Collard HR; Costabel U; Richeldi L; de Andrade J; Khalil N; Morrison LD; Lederer DJ; Shao L; Li X; Pedersen PS; Montgomery AB; Chien JW; O'Riordan TG;
Ann Intern Med; 2013 May; 158(9):641-9. PubMed ID: 23648946
[TBL] [Abstract][Full Text] [Related]
23. An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report.
Enomoto N; Chida K; Suda T; Kaida Y; Taniguchi M; Azuma A; Hayashi H; Ogura T; Kitamura H; Yamaguchi O; Ando M; Sato A; Kudo S
Clin Respir J; 2016 Nov; 10(6):746-755. PubMed ID: 25689162
[TBL] [Abstract][Full Text] [Related]
24. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA
Respir Res; 2015 Sep; 16():116. PubMed ID: 26400368
[TBL] [Abstract][Full Text] [Related]
25. Interferon gamma for idiopathic pulmonary fibrosis.
Bouros D
Lancet; 2009 Jul; 374(9685):180-2. PubMed ID: 19570574
[No Abstract] [Full Text] [Related]
26. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
27. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
Raghu G; Martinez FJ; Brown KK; Costabel U; Cottin V; Wells AU; Lancaster L; Gibson KF; Haddad T; Agarwal P; Mack M; Dasgupta B; Nnane IP; Flavin SK; Barnathan ES
Eur Respir J; 2015 Dec; 46(6):1740-50. PubMed ID: 26493793
[TBL] [Abstract][Full Text] [Related]
28. New perspectives in the treatment of idiopathic pulmonary fibrosis.
Rogliani P; Mura M; Assunta Porretta M; Saltini C
Ther Adv Respir Dis; 2008 Apr; 2(2):75-93. PubMed ID: 19124361
[TBL] [Abstract][Full Text] [Related]
29. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
Raghu G; Brown KK; Bradford WZ; Starko K; Noble PW; Schwartz DA; King TE;
N Engl J Med; 2004 Jan; 350(2):125-33. PubMed ID: 14711911
[TBL] [Abstract][Full Text] [Related]
30. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
31. [Evolution of IGRA researches].
Ariga H; Harada N
Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
[TBL] [Abstract][Full Text] [Related]
32. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
Azuma A
Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
Harari S; Caminati A; Albera C; Vancheri C; Poletti V; Pesci A; Luppi F; Saltini C; Agostini C; Bargagli E; Sebastiani A; Sanduzzi A; Giunta V; Della Porta R; Bandelli GP; Puglisi S; Tomassetti S; Biffi A; Cerri S; Mari A; Cinetto F; Tirelli F; Farinelli G; Bocchino M; Specchia C; Confalonieri M
Respir Med; 2015 Jul; 109(7):904-13. PubMed ID: 25962649
[TBL] [Abstract][Full Text] [Related]
34. Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis.
Bajwa EK; Ayas NT; Schulzer M; Mak E; Ryu JH; Malhotra A
Chest; 2005 Jul; 128(1):203-6. PubMed ID: 16002936
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and pharmacokinetics of continuous subcutaneous infusion of low-dose interferon-gamma: a pilot study.
Satake I; Tari K; Nakagomi K; Ozawa K
Jpn J Clin Oncol; 1993 Dec; 23(6):356-62. PubMed ID: 8283789
[TBL] [Abstract][Full Text] [Related]
36. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.
Raghu G; Brown KK; Costabel U; Cottin V; du Bois RM; Lasky JA; Thomeer M; Utz JP; Khandker RK; McDermott L; Fatenejad S
Am J Respir Crit Care Med; 2008 Nov; 178(9):948-55. PubMed ID: 18669816
[TBL] [Abstract][Full Text] [Related]
37. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Daniels CE; Lasky JA; Limper AH; Mieras K; Gabor E; Schroeder DR;
Am J Respir Crit Care Med; 2010 Mar; 181(6):604-10. PubMed ID: 20007927
[TBL] [Abstract][Full Text] [Related]
38. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
Justice JN; Nambiar AM; Tchkonia T; LeBrasseur NK; Pascual R; Hashmi SK; Prata L; Masternak MM; Kritchevsky SB; Musi N; Kirkland JL
EBioMedicine; 2019 Feb; 40():554-563. PubMed ID: 30616998
[TBL] [Abstract][Full Text] [Related]
39. [Idiopathic pulmonary fibrosis (IPF)].
Matsumoto A; Azuma A
Nihon Rinsho; 2006 Jul; 64(7):1354-60. PubMed ID: 16838656
[TBL] [Abstract][Full Text] [Related]
40. Interferon-gamma 1b: impact of new indications (idiopathic pulmonary fibrosis).
Aggarwal AN; Behera D
Expert Opin Pharmacother; 2000 Dec; 1(7):1423-7. PubMed ID: 11249475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
